Chronic kidney disease (CKD) includes various conditions affecting the structure and function of the kidneys. In 2002, a significant paradigm shift occurred, recognizing CKD as a critical global public health issue and highlighting the necessity of early intervention by general internists. The classification and management of CKD are based on stages that reflect the severity of the condition, assessed through the glomerular filtration rate (GFR), albuminuria, and clinical diagnosis (including cause and pathology). Routine laboratory tests can identify CKD, and specific treatments exist to prevent its progression, reduce complications associated with decreased GFR and cardiovascular risks, and improve survival rates and quality of life (
1). Chronic kidney disease represents a considerable health burden worldwide, affecting about 10 - 15% of the population. It stands as a leading cause of morbidity and mortality among non-communicable diseases. Early detection of CKD is essential for reducing its negative impact on patients' health. By promptly and accurately diagnosing CKD, healthcare providers can timely administer appropriate treatments, lowering the risk of complications, such as hypertension, anemia, mineral bone disorder, poor nutritional status, acid-base imbalances, and neurological complications. Early intervention is crucial for alleviating these health issues and enhancing patient outcomes (
2).
Artificial intelligence (AI) equips computer programs with the capability to perform tasks and reason in ways akin to human intelligence. It excels in making precise decisions in the face of ambiguity, uncertainty, and large volumes of data. In healthcare, where an abundance of data, such as clinical symptoms and imaging features, is present, machine learning (ML) algorithms come into play to organize and classify this information effectively. Essentially, ML is a technique that utilizes pattern recognition to assist in this process (
3). Healthcare organizations are adopting machine-learning methods, like artificial neural networks (ANNs), to improve the quality of care while reducing costs. Artificial neural network is widely recognized for its diagnostic applications, but its use is extending to support decision-making in healthcare management. This successful integration of ANN enables healthcare providers to make informed and efficient decisions, benefiting both patients and the overall healthcare system (
4).
Debal and Sitote (
2) compared the performance of random forest (RF), support vector machine (SVM), and decision tree (DT) models in predicting CKD. Their findings indicated that the RF model surpassed traditional models in accuracy and predictive power, suggesting that using the RF model could enhance CKD predictions over conventional methods. Bai et al. (
5) aimed to determine whether ML could effectively predict the risk of end-stage renal disease (ESKD) in patients with CKD. They tested five ML algorithms (logistic regression, simple Bayes, RF, DT, and K-nearest neighbor) using five-fold cross-validation. The performance of each model was compared to the kidney failure risk equation (KFRE). The results showed that three ML models, specifically logistic regression, simple Bayes, and RF, had comparable predictive abilities and higher sensitivity compared to KFRE. Yashfi et al. (
6) analyzed the records of 455 patients using two models, RF and ANN, to predict the risk of CKD. Their analysis found that the RF model achieved an impressive accuracy rate of 97%, while the ANN model had an accuracy of 94%.
According to the study by Islam et al. (
7), the XGBoost model was found to surpass other models, like RF and CatBoost (CB), in predicting the risk of CKD, demonstrating an impressive accuracy rate of 98%. Singh et al. (
8) introduced an innovative deep neural model that accurately predicts the risk of CKD, notably incorporating a range of critical characteristics, such as hemoglobin, specific gravity, serum creatinine, red blood cell count, albumin, packed cell volume, and blood pressure. Their comprehensive approach significantly enhanced the accuracy of disease predictions. Almansour et al. (
9) applied ANN and SVM techniques in their research, addressing missing values by substituting them with the feature means in the dataset. They meticulously fine-tuned ANN and SVM by adjusting parameters through extensive experimentation to identify optimal configurations. Their efforts resulted in reliable models for both techniques, with experimental results showing that ANN outperformed SVM, achieving an extraordinary accuracy of 99.75%, while SVM attained 97.75% accuracy.
Mondol et al. (
10) compared various optimized neural networks against conventional neural networks to identify the most effective model for a specific task. Their findings indicated that optimized models generally performed better than traditional models. Among the conventional models evaluated, the convolutional neural network (CNN) recorded the highest validation accuracy of 92.71%. However, the optimized models, including the optimized convolutional neural network (OCNN), optimized ANN (OANN), and optimized long short-term memory (OLSTM), achieved even higher accuracies of 98.75%, 96.25%, and 98.5%, respectively. Notably, the OCNN model secured the highest area under the curve (AUC) score of 0.99, showcasing superior performance. It also demonstrated the shortest data collection time for classification, at only 0.00447 seconds, marking it as the most efficient model for CKD detection.